Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (21-30 of 218) with videos related to

Pageof 22
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2016
Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen StudieJutta Huebner, Peter Mohr, Jan-Christoph Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2016
Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trialJutta Huebner, Peter Mohr, Jan-Christoph Simon, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2018
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeLaura Milsch, Anja Gesierich, Sophia Kreft, et al.
Frontiers in Oncology|December 2, 2020
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case ReportJohanna Matull, Elisabeth Livingstone, Axel Wetter, et al.
British Journal of Pharmacology|March 11, 2026
Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio-oncology RegistryElias Haj-Yehia, Lisa Zimmer, Lena Lampe, et al.
Diagnostic Pathology|May 23, 2013
Lack of SF3B1 R625 mutations in cutaneous melanomaBastian Schilling, Nicola Bielefeld, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Dose-dependent toxicity of ipilimumab in metastatic melanomaAlexandra Olischewsky, Sofie De Schrijver, Agnes Bankfalvi, et al.
Microorganisms|March 6, 2021
Impact of the Histidine-Containing Phosphocarrier Protein HPr on Carbon Metabolism and Virulence in <i>Staphylococcus aureus</i>Linda Pätzold, Anne-Christine Brausch, Evelyn-Laura Bielefeld, et al.
European Radiology|May 15, 2013
Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?Carolin Gramsch, Sophia L Göricke, Felix Behrens, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Pageof 22

Showing results (21-30 of 218) with videos related to

Sort By:
Pageof 22
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2016
Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen StudieJutta Huebner, Peter Mohr, Jan-Christoph Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2016
Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trialJutta Huebner, Peter Mohr, Jan-Christoph Simon, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2018
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeLaura Milsch, Anja Gesierich, Sophia Kreft, et al.
Frontiers in Oncology|December 2, 2020
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case ReportJohanna Matull, Elisabeth Livingstone, Axel Wetter, et al.
British Journal of Pharmacology|March 11, 2026
Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio-oncology RegistryElias Haj-Yehia, Lisa Zimmer, Lena Lampe, et al.
Diagnostic Pathology|May 23, 2013
Lack of SF3B1 R625 mutations in cutaneous melanomaBastian Schilling, Nicola Bielefeld, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Dose-dependent toxicity of ipilimumab in metastatic melanomaAlexandra Olischewsky, Sofie De Schrijver, Agnes Bankfalvi, et al.
Microorganisms|March 6, 2021
Impact of the Histidine-Containing Phosphocarrier Protein HPr on Carbon Metabolism and Virulence in <i>Staphylococcus aureus</i>Linda Pätzold, Anne-Christine Brausch, Evelyn-Laura Bielefeld, et al.
European Radiology|May 15, 2013
Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?Carolin Gramsch, Sophia L Göricke, Felix Behrens, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Pageof 22